drugset / Trial / NCT01194271
Neoadjuvant Ipilimumab in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn how ipilimumab in combination with Lupron (leuprolide acetate) affects the body's own defense (immune) system before having surgery to remove prostate cancer. The safety of the drug combination will also be studied.
Timeline
- Start
- 2010-09
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Leuprolide | Other / unclassified | 22.5 mg | Intramuscular |